Scinai Immunotherapeutics Holds Shareholder Meeting

TL;DR

Scinai held a shareholder meeting on Aug 12, 2024 with over 3.3B shares eligible to vote.

AI Summary

On August 12, 2024, Scinai Immunotherapeutics Ltd. held an Extraordinary Meeting of Shareholders. The total number of ordinary shares eligible to vote was 3,349,222,240.

Why It Matters

This filing indicates a formal shareholder meeting took place, which is a standard corporate governance event for companies.

Risk Assessment

Risk Level: low — The filing is a routine report of a shareholder meeting and does not contain significant new financial or operational information.

Key Numbers

• 3,349,222,240 — Ordinary Shares (Eligible to vote at the Extraordinary Meeting of Shareholders on August 12, 2024.)

Key Players & Entities

• Scinai Immunotherapeutics Ltd. (company) — Registrant
• August 12, 2024 (date) — Date of Shareholder Meeting
• 3,349,222,240 (dollar_amount) — Number of Ordinary Shares Entitled to Vote

FAQ

From the Filing

0001213900-24-067584.txt : 20240812 0001213900-24-067584.hdr.sgml : 20240812 20240812141336 ACCESSION NUMBER: 0001213900-24-067584 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240812 FILED AS OF DATE: 20240812 DATE AS OF CHANGE: 20240812 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Scinai Immunotherapeutics Ltd. CENTRAL INDEX KEY: 0001611747 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37353 FILM NUMBER: 241196155 BUSINESS ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 BUSINESS PHONE: 972-8-9302529 MAIL ADDRESS: STREET 1: JERUSALEM BIOPARK, 2ND FLOOR STREET 2: HADASSAH EIN KEREM CAMPUS CITY: JERUSALEM STATE: L3 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: BiondVax Pharmaceuticals Ltd. DATE OF NAME CHANGE: 20140624 6-K 1 ea0211152-6k_scinai.htm REPORT OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month of August 2024 Commission File Number: 001-37353 SCINAI IMMUNOTHERAPEUTICS LTD. (Translation of registrant’s name into English) Jerusalem BioPark, 2nd Floor Hadassah Ein Kerem Campus Jerusalem, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐ On August 12, 2024, Scinai Immunotherapeutics Ltd . (the “Company”) held an Extraordinary Meeting of Shareholders (the “Meeting”). The total number of ordinary shares of the Company entitled to vote at the Meeting was 3,349,222,240 Ordinary Shares (each 4,000 Ordinary Shares represented by one American Depository Share ("ADS")) and there were present, in person or by proxy, 715,512,000 ordinary shares, which constituted a quorum for the Meeting. The matters voted upon, and the results of the vote were as follows: Proposal 1: To approve amendments to the Company’s articles of association to authorize the creation of preferred shares, no par value per share, of the Company (“Preferred Shares”), and to approve the issuance of Preferred Shares in connection with a debt-to-equity conversion transaction with the European Investment Bank (the “EIB Transaction”), all subject to the consummation of the EIB Transaction”. The shareholders approved amendments to the Company’s articles of association to authorize the creation of Preferred Shares, and to approve the issuance of Preferred Shares in connection with the EIB Transaction, all subject to the consummation of the EIB Transaction: FOR AGAINST ABSTAIN 701,224,000 (175,306 ADSs) 12,784,000 (3,196 ADSs) 1,504,000 (376 ADSs) At least 75% of the voting power represented at the Meeting, in person or by proxy, and voting on the matter presented, voted in favor of Proposal 1. Proposal 2: Approval of a grant of 17,909 restricted share units to Amir Reichman, Chief Executive Officer of the Company, as Mr. Reichman’s long-term incentive grant award for 2023. The shareholders approved a grant of 17,909 restricted share units to Amir Reichman, Chief Executive Officer of the Company, as Mr. Reichman’s long-term incentive grant award for 2023: FOR AGAINST ABSTAIN 679,168,000 (169,792 ADSs) 32,340,000 (8,085 ADSs) 4,004,000 (1,001 ADSs) The total number of votes of the holders that are not controlling shareholders and do not have a personal interest in approval of the proposal that are voted against such proposal does not exceed two percent (2%) of the total voting rights in the Company. In addition, the majority v